Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo

References

• He J, Gu Y, Zhang S. Consumption of vegetables and fruits and breast cancer survival: a systematic review and meta-analysis. Sci Rep. 2017;7.
   Web of Science ®Google Scholar
• Yang C, Wang M, Zhou J, et al. Bio-synthesis of peppermint leaf extract polyphenols capped nano-platinum and their in-vitro cytotoxicity towards colon cancer cell lines (HCT 116). Mater Sci Eng C Mater Biol Appl. 2017;77:1012–1016.
   PubMed Web of Science ®Google Scholar
• Sun P, Sun D, Wang X. Effects of Scutellaria barbata polysaccharide on the proliferation, apoptosis and EMT of human colon cancer HT29 Cells. Carbohydr Poly. 2017;167:90–96.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li G, Gao M, et al. RGD-peptide conjugated inulin-ibuprofen nanoparticles for targeted delivery of Epirubicin. Coll Surf B: Biointerf. 2016;144:81–89.
   PubMed Web of Science ®Google Scholar
• Di-Wen S, Pan G-Z, Hao L, et al. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric nanoparticles in liver cancers. Int J Pharma. 2016;500:54–61.
   PubMed Web of Science ®Google Scholar
• Langer R. Science's compass-perspectives-drug delivery: drugs on target. Sci-Int Ed-AAAS. 2001;293:58–58.
   Google Scholar
• Langer R. Drug delivery and targeting. Nature 1998;5–10.
   PubMed Web of Science ®Google Scholar
• Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Rel. 2010;148:135–146.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Lefoulon F. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Dis Today. 2004;9:219–228.
   PubMed Web of Science ®Google Scholar
• Gu FX, Karnik R, Wang AZ, et al. Targeted nanoparticles for cancer therapy. Nano Today. 2007;2:14–21.
   Web of Science ®Google Scholar
• Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483–489.
   PubMed Web of Science ®Google Scholar
• Brody EN, Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol. 2000;74:5–13.
   PubMedGoogle Scholar
• Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt (IV) prodrug-PLGA–PEG nanoparticles. Proc Nat Acad Sci USA. 2008.
   Web of Science ®Google Scholar
• Bagalkot V, Farokhzad OC, Langer R, et al. An aptamer–doxorubicin physical conjugate as a novel targeted drug‐delivery platform. Angew Chem. 2006;118:8329–8332.
   Google Scholar
• Yazdian-Robati R, Ramezani M, Jalalian SH, et al. Targeted delivery of epirubicin to cancer cells by polyvalent aptamer system in vitro and in vivo. Pharm Res. 2016;33:2289–2297.
   PubMed Web of Science ®Google Scholar
• Taghdisi SM, Danesh NM, Ramezani M, et al. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo. Eur J Pharm Biopharm. 2016;102:152–158.
   PubMed Web of Science ®Google Scholar
• Plourde K, Derbali RM, Desrosiers A, et al. Aptamer-based liposomes improve specific drug loading and release. J Control Rel. 2017;251:82–91.
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Nguyen TH, Do DH, et al. Characterization of the paclitaxel loaded chitosan graft Pluronic F127 copolymer micelles conjugate with a DNA aptamer targeting HER-2 overexpressing breast cancer cells. Adv Nat Sci: Nanosci Nanotechnol. 2017;8:015002.
   Google Scholar
• Wang H, Zhao Y, Wu Y, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011;32:8281–8290.
   PubMed Web of Science ®Google Scholar
• Xiao W, Chen X, Yang L, et al. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome. Int J Pharma. 2010;393:120–127.
   Web of Science ®Google Scholar
• Wang C, Chen T, Zhang N, et al. Melittin, a major component of bee venom, sensitizes human hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating CaMKII-TAK1-JNK/p38 and inhibiting IκBα kinase-NFκB. J Biol Chem. 2009;284:3804–3813.
   PubMed Web of Science ®Google Scholar
• Terra RM, Guimarães JA, Verli H. Structural and functional behavior of biologically active monomeric melittin. J Mol Graphics Model. 2007;25:767–772.
   PubMed Web of Science ®Google Scholar
• Park JH, Jeong Y-J, Park K-K, et al. Melittin suppresses PMA-induced tumor cell invasion by inhibiting NF-kappaB and AP-1-dependent MMP-9 expression. Mol Cells. 2010;29:209–215.
   PubMed Web of Science ®Google Scholar
• Park MH, Choi MS, Kwak DH, et al. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB. Prostate. 2011;71:801–812.
   PubMed Web of Science ®Google Scholar
• Jo M, Park MH, Kollipara PS, et al. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol Appl Pharmacol. 2012;258:72–81.
   PubMed Web of Science ®Google Scholar
• Liu S, Yu M, He Y, et al. Melittin prevents liver cancer cell metastasis through inhibition of the Rac1‐dependent pathway. Hepatology. 2008;47:1964–1973.
   PubMed Web of Science ®Google Scholar
• Jeong Y-J, Choi Y, Shin J-M, et al. Melittin suppresses EGF-induced cell motility and invasion by inhibiting PI3K/Akt/mTOR signaling pathway in breast cancer cells. Food Chem Toxicol. 2014;68:218–225.
   PubMed Web of Science ®Google Scholar
• Hait WN, Grais L, Benz C, et al. Inhibition of growth of leukemic cells by inhibitors of calmodulin: phenothiazines and melittin. Cancer Chemother Pharmacol. 1985;14:202–205.
   PubMed Web of Science ®Google Scholar
• Son DJ, Lee JW, Lee YH, et al. Therapeutic application of anti-arthritis, pain-releasing, and anti-cancer effects of bee venom and its constituent compounds. Pharmacol Ther. 2007;115:246–270.
   PubMed Web of Science ®Google Scholar
• Qi C, Zhu YJ, Lu BQ, et al. ATP‐stabilized amorphous calcium carbonate nanospheres and their application in protein adsorption. Small. 2014;10:2047–2056.
   PubMed Web of Science ®Google Scholar
• Lee K, Wagermaier W, Masic A, et al. Self-assembly of amorphous calcium carbonate microlens arrays. Nat Commun. 2012;3:725.
   PubMed Web of Science ®Google Scholar
• Maleki Dizaj S, Barzegar-Jalali M, Zarrintan MH, et al. Calcium carbonate nanoparticles as cancer drug delivery system. Exper Opinion Drug Deliv. 2015;12:1649–1660.
   PubMed Web of Science ®Google Scholar
• Zhou C, Chen T, Wu C, et al. Aptamer CaCO3 nanostructures: a facile, pH‐responsive, specific platform for targeted anticancer theranostics. Chem Asian J. 2015;10:166–171.
   PubMed Web of Science ®Google Scholar
• Rady I, Siddiqui IA, Rady M, et al. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett. 2017;402:16–31.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997;54:1–7.
   PubMed Web of Science ®Google Scholar